The private equity market will likely drive IPO volumes higher than 2024, but the strength of the PE market could cap the ...

Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

End of the customary 25-day period after an IPO during which the major analyst firms who have been involved in the IPO do not publish research on the company. Lockup Exp.

CX Partners backed Veeda Clinical Research, a full-service contract research organization (CRO) has refiled its Draft Red ...

Immunome (IMNM) intends to raise $30 million in an IPO of its common stock ... According to a 2018 market research report by Global Market Insights, the global market for biological treatments ...

The midpoint of the expected IPO price range would give Smithfield ... We also reference original research from other reputable publishers where appropriate. You can learn more about the standards ...

Beyond using AI to draft IPO prospectuses to court potential ... and cutting down on redundancies in the equity-research example would be "a massive process change." "It's hard, because people ...

IPO Watch: Veeda Clinical Research has refiled its draft prospectus for an IPO with SEBI, seeking to raise ₹185 crore. (Image: Pixabay) IPO Watch: Veeda Clinical Research has refiled its draft ...